Advocacy intelligence hub — real-time data for patient organizations
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Istanbul University
University of Child Health Sciences and Children's Hospital, Lahore — PHASE3
Duke University — PHASE3
Novartis Pharmaceuticals
Consorci Sanitari de l'Alt Penedès i Garraf
University of the West of England
Hacettepe University
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance11
DEXAMETHASONE SODIUM PHOSPHATE
Merck
Mobic
Avondale Pharmaceuticals
ORENCIA
Bristol Myers Squibb
Rinvoq
AbbVie
ENBREL
Amgen
Kineret
Sobi
SIMPONI ARIA
Janssen
METHOTREXATE
Unknown
Adalimumab
AbbVie
Simponi
Janssen
Humira
AbbVie
Mobic
(meloxicam)Orphan drugAvondale Pharmaceuticals
Nonsteroidal Anti-inflammatory Drug [EPC]
12.1 Mechanism of Action Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of ot...
Enbrel
(etanercept)Orphan drugImmunex Corporation
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important rol...
PIROXICAM
(PIROXICAM)standardUnichem Pharmaceuticals (USA), Inc.
Nonsteroidal Anti-inflammatory Drug [EPC]
12.1 Mechanism of Action Piroxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of piroxicam capsules, like t...
Methotrexate
(Methotrexate sodium)Orphan drugstandardLederle Laboratories
12.1 Mechanism of Action Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before ...
SIMPONI ARIA�
(golimumab)Orphan drugstandardJanssen Research & Development, LLC
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This...
Remicade
(infliximab)Orphan drugstandardJanssen Biotech, Inc.
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...
Orencia
(abatacept)Orphan drugstandardBristol-Myers Squibb Co.
Selective T Cell Costimulation Modulator [EPC]
12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereb...
Actemra
(tocilizumab)Orphan drugstandardGenentech, Inc.
Interleukin-6 Receptor Antagonist [EPC]
12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...
FDA Approves PIROXICAM
PIROXICAM (PIROXICAM) received FDA approval.
High Health Care Utilization Preceding Diagnosis With Juvenile Idiopathic Arthritis.
Although early diagnosis improves long-term outcomes, patients with juvenile idiopathic arthritis (JIA) often experience prolonged, circuitous paths to diagnosis. To inform diagnostic improvement, we ...
Simplified MRI scoring system for TMJ assessment in juvenile idiopathic arthritis.
The temporomandibular joint (TMJ) is a small, yet complex joint. MRI interpretation of TMJ involvement in children with juvenile idiopathic arthritis (JIA) is challenging but essential for the diagnos...
Comprehensive evaluation of juvenile idiopathic arthritis using whole-body MRI: a prospective cross-sectional analysis.
To evaluate the role of whole-body magnetic resonance imaging (WBMRI) using a noninvasive, non-contrast protocol in detecting clinical and subclinical inflammation in pediatric patients with juvenile ...
Clinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.
Analyze the clinical and laboratory characteristics of childhood-onset systemic lupus erythematosus (cSLE) complicated by macrophage activation syndrome (MAS), evaluate the applicability of the 2016 E...
Methotrexate Therapy in Juvenile Idiopathic Arthritis: No Clinically Relevant Pulmonary Impairment but Frequent Transient Liver Enzyme Elevations in a Longitudinal Single-Center Pediatric Cohort of 274 Children Over 30 Years.
Methotrexate (MTX) is a cornerstone in treating juvenile idiopathic arthritis (JIA). The long-term impact of MTX, particularly on pulmonary and liver function, remains a concern. We longitudinally exa...
Yan Li, PhD
Oregon Health and Science University
Gil Amarilyo, MD
Schneider Children Medical Center of Israel
Roberta Berard, MD
LHSC Children's Hospital/ Lawson Research
Peter Malleson, MD
University of British Columbia
Nora G Singer, MD, MD
UHospitals Cleveland
📍 CLEVELAND, OH
Laura S Hillman, MD
University of Missouri-Columbia